BACKGROUND: Indoxyl sulphate (IS) and pcresylsulphate (PCS) are uremic toxins with similar proteinbinding, dialytic clearance, and proinflammatory features. Few studies have evaluated the possible associations between these solutes and coronary artery disease (CAD) in type 2 diabetes (T2D) patients. METHODS: A hospitalbased case control study was performed. A total of 209 T2D patients were divided into two groups based on the presence/absence of significant CAD (≥50% luminal reduction). Serum total PCS and IS levels were measured using the Ultra Performance LC System. The relationship between total PCS and IS levels were investigated. Coronary calcium scores and the modified Gensini score were analyzed. RE-SULTS: Serum total PCS and IS levels were significantly higher in patients with both T2D and significant CAD, than in non-diabetic control subjects and T2D patients without CAD (all p < 0.05). Logistic regression analysis revealed independent and significant associations between the two solutes and CAD status. Serum total PCS, IS, and numbers of diseased vessels were elevated in groups with estimated glomerular filtration rate (eGFR) of 60-89 ml/min/1.73 m 2 and below. Also, serum total PCS and IS levels were significantly associated with eGFR, coronary calcium scores, Gensini score, adipocytokines (adiponectin, visfatin, and leptin), and total white blood cell count. CONCLUSIONS: Serum total PCS and IS levels were elevated in patients with T2D and CAD. These increases were associated with renal function deterioration, inflammation, and coronary atherosclerosis.
Introduction
he main cause of death in diabetic patients is cardiovascular disease [1] . Loss of kidney function is due to diabetic nephropathy. When diabetic renal failure develops, several harmful uremic retention solutes accumulate in the circulation. This accumulation may play a di-gested phenylalanine and plant phenols. In humans, it exists predominantly as the conjugate PCS [4] . IS is an organic anion metabolized in the liver and originates from indole, which is produced by intestinal bacteria as a metabolite of tryptophan [5] . In uremic patients, serum levels of PC and IS are elevated approximately 10-fold [6] and 50-fold [7] , respectively, because of their strong protein binding ability, and poor clearance from the kidney and during conventional hemodialysis [8] . PCS and IS have been widely investigated for their contributions the pathogenesis of vascular injury via endothelial dysfunction [9, 10] , proliferation of vascular smooth muscle cells [11] , activation of atherosclerotic pro-inflammatory markers [12] , and suppression of endothelial repair [13] . These findings indicate that these two protein-bound uremic toxins induce the initiation and/or progression of atherosclerosis. Moreover, our recent study demonstrated that higher total PCS levels were associated with the severity of coronary atherosclerosis in patients with stable angina in the early stages of chronic kidney disease [14] . Atoh et al. confirmed that IS was already elevated at the time of early type 2 diabetic nephropathy (estimated glomerular filtration rate (eGFR) of 60-89 ml/min/1.73 m 2 ) [2] . However, the relationship between serum total PCS and IS levels and coronary atherosclerotic development in T2D patients is not understood at the moment.
In the present study, we investigated the hypothesis that total PCS and IS levels are associated with coronary atherosclerotic development in T2D patients. We assessed serum total PCS and IS levels, modified Gensini scores, and coronary artery calcium scores (as measured by cardiac multi-slice computed tomography) in a cohort of T2D patients. We further examined whether total PCS and IS levels might be associated with selected atherosclerotic inflammatory cytokines, and traditional cardiovascular risk markers in this population.
Subjects and methods

Subjects
This study included 209 patients who underwent coronary angiography between June 2007, and December 2010, for the diagnosis and interventional treatment of coronary artery disease (CAD) in diabetic, or cardiovascular, clinics of E-Da Hospital. Diagnosis of T2D was based on World Health Organization criteria [15] . Patients were excluded who presented with type 1 diabetes symptoms, such as diabetic ketoacidosis, acute ketonuria, or continuous insulin requirements within one year of diagnosis. Also, patients with histories of concomitant valvular disease, congenital heart disease, or cardiomyopathy, and those who refused to provide informed consent were excluded. Subjects without clinical evidence of major diseases, including T2D, renal disease, cerebrovascular disease, and CAD, who underwent routine medical check-ups were randomly recruited as control subjects. Non-diabetic subjects were defined as individuals with fasting plasma glucose lower than 100 mg/dl, no diabetes history, and absence of familial T2D history. Individuals were considered as non-CAD if they had undergone coronary angiographic examination, and if insignificant coronary stenosis was documented. Detailed personal disease history and family history were obtained from all study subjects under the supervision of trained personnel. Questionnaires were checked for proper completion and plausibility. This case-control study was approved
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Blood pressure (BP) was measured in the morning (two readings at least 2 min apart) at the right upper arm in line with the heart, with the subjects seated and after at least 5 min of rest. BP measurement was carried out using a mercury column sphygmomanometer. The average values of these measurements were recorded for analysis.
Hypertension was defined as systolic BP (SBP) of ≥140 mmHg, diastolic BP of ≥90 mmHg, or both, or intake of anti-hypertensive drugs. Dyslipidemia was defined as follows:
-triglyceride level of ≥150 mg/dl, and/or -high-density lipoprotein (HDL) cholesterol level of <35 mg/dl for men and <39 mg/dl for women, and/or -total cholesterol level of ≥200 mg/dl, and/or -low-density lipoprotein cholesterol level of ≥130 mg/dl, or -those undergoing treatment for lipid disorders according to the criteria of NCEP-ATP-III [16] .
Patient smoking status was classified as (i) individuals who never smoked, (ii) former smokers (ceased smoking for at least 1 year), or (iii) current smokers. In this study, former and current smokers were analyzed as a group, and compared with those who had never smoked.
Angiographic definitions
Coronary angiograms were obtained according to standard techniques. The severity of stenosis was assessed using quantitative coronary angiography. Angiograms and quantitative coronary angiographic analyses were evaluated by at least 2 experienced interventional cardiologists blinded to clinical information and serologic parameters. Angiographic outcomes were scored according to the following two systems:
1. The possible scores of this index ranged from 0 to 3 diseased vessels. The criterion for 1-, 2-, or 3-vessel disease was a ≥50% luminal reduction of the right coronary artery. The stenosis of the left main coronary artery did not exceed 50%. 2. In the modified Gensini scoring system, weights are assigned to each coronary segment depending on vessel size and importance, and range from 0.5 to 5.0. Segments serving larger regions of the myocardium are more heavily weighted. The narrowing of the coronary artery lumen is rated as follows:
i) 2 for 0-25% stenosis, ii) 4 for 26-50% stenosis, iii) 8 for 51-75% stenosis, iv) 16 for 76-90% stenosis, v) 32 for 91-99% stenosis, and vi) 64 for 100% stenosis.
The modified Gensini index is the sum of the total weights for each segment [17, 18] .
Calculation of coronary calcium score on coronary CT angiography
Agatston calcium scores were measured for 75 randomly selected subjects by using coronary artery calcification-scoring software (SmartScore). The Agatston calcium score was obtained by multiplying the area by a weighting factor, dependent on the peak signal anywhere in the lesion. The scores for individual lesions were added to obtain the Agatston calcium score for the entire coronary tree. The total calcium volume was calculated by multiplying the area of the calcified lesion (mm 2 ) by section thickness [18] .
Laboratory measurements
Peripheral blood samples were taken from an antecubital vein after admission to the hospital. Blood for total PCS and IS determinations was obtained, centrifuged, and stored at -80°C for subsequent assay. Before coronary angiography, complete blood counts, serum creatinine profiles, and serum lipid profiles were determined for all patients. Plasma triglycerides, total cholesterol, lowdensity lipoprotein cholesterol (LDL-C), highdensity lipoprotein cholesterol (HDL-C), uric acid, albumin, creatinine, and glucose were measured by standard commercial methods on a parallel multichannel analyzer (SYNCHRON, Los Angeles, CA, USA), as described in our previous reports [19] .
Serum samples were deproteinized by adding 3 parts methanol to 1 part serum, for determination of total PCS and IS. All analyses were performed on a Waters Acquity Ultra Performance Liquid Chromatography (UPLC) system (Milford, MA, USA). UPLC assays using detection at 280 nm for IS, and 260 nm for PCS, were performed at room temperature on an Acquity UPLC bridged ethyl hybrid (BEH) phenyl column of 2.1 x 100 mm. The column temperature was maintained at 30°C. The buffer flow was 0.4 ml/min using 10 mM NH 4 H 2 PO 4 (pH = 4.0) (A) and acetonitrile (B), with a gradient running from 82.5%A/17.5%B to 55%A/45%B over 9 min. Under these conditions, IS and PCS appeared at 1.4 min and 1.7 min, respectively. The limits of detection of this assay were 0.225 mg/l for IS and 1 mg/l for PCS. Calibration curves were constructed by plotting the peak areas versus the concentrations of each analysate. The average r 2 values were 0.999 ± 0.001. Quantitative results were obtained and calculated as concentrations (mg/l). Intra-and inter-assay coefficients of variation (relative standard deviation) were 0.4% and 0.05% for IS, and 5.50% and 7.48% for PCS, respectively. Parallel comparisons of serum total PCS and IS levels, obtained from UPLC and mass spectrometry (MS) in 10 randomly selected patients, were in agreement with Bland-Altman plots. For serum IS, Pitman's test of difference in variance showed r = -0.263 and p = 0.493 (for serum PCS, r = -0.765 and p = 0.124) [14, 20, 21] .The concentration of plasma visfatin was determined using a commercial enzyme immunoassay kit (Phoenix Pharmaceuticals, Beland mass spectrometry (MS) in 10 randomly selected patients, were in agreement with Bland-Altman plots. For serum IS, Pitman's test of difference in variance showed r = -0.263 and p = 0.493 (for serum PCS, r = -0.765 and p = 0.124) [14, 20, 21] .The concentration of plasma visfatin was determined using a commercial enzyme immunoassay kit (Phoenix Pharmaceuticals, Beland mass spectrometry (MS) in 10 randomly selected patients, were in agreement with Bland-Altman plots. For serum IS, Pitman's test of difference in variance showed r = -0.263 and p = 0.493 (for serum PCS, r = -0.765 and p = 0.124) [14, 20, 21] .The concentration of plasma visfatin was determined using a commercial enzyme immunoassay kit (Phoenix Pharmaceuticals, Beland mass spectrometry (MS) in 10 randomly selected patients, were in agreement with Bland-Altman plots. For serum IS, Pitman's test of difference in variance showed r = -0.263 and p = 0.493 (for serum PCS, r = -0.765 and p = 0.124) [14, 20, 21] .The concentration of plasma visfatin was determined using a commercial enzyme immunoassay kit (Phoenix Pharmaceuticals, Beland mass spectrometry (MS) in 10 randomly selected patients, were in agreement with Bland-Altman plots. For serum IS, Pitman's test of difference in variance showed r = -0.263 and p = 0.493 (for serum PCS, r = -0.765 and p = 0.124) [14, 20, 21] . The concentration of plasma visfatin was determined using a commercial enzyme immunoassay kit (Phoenix Pharmaceuticals, Beland mass spectrometry (MS) in 10 randomly selected patients, were in agreement with Bland-Altman plots. For serum IS, Pitman's test of difference in variance showed r = -0.263 and p = 0.493 (for serum PCS, r = -0.765 and p = 0.124) [14, 20, 21] . The concentration of plasma visfatin and mass spectrometry (MS) in 10 randomly selected patients, were in agreement with Bland-Altman plots. For serum IS, Pitman's test of difference in variance showed r = -0.263 and p = 0.493 (for serum PCS, r = -0.765 and p = 0.124) [14, 20, 21] . The concentration of plasma visfatin was determined using a commercial enzyme immunoassay kit (Phoenix Pharmaceuticals, Belmont, CA, USA). Adiponectin and leptin levels were determined by commercial solid-phase enzyme-linked immunosorbent assay kits (B-Bridge International, Sunnyvale, CA, USA; Phoenix Pharmaceuticals, Belmont, CA, USA; and R&D Systems, Inc., USA). The concentration of plasma C-reactive protein (CRP) was measured using a high-sensitivity method (IMMAGE; Beckman Coulter, Immunochemistry Systems, Brea, CA, USA). The intra-assay coefficients of variation were 2.4-2.7% for visfatin, 3.2-7.3% for adiponectin, 3.2-6.9% for leptin, and 4.2-8.7% for hs-CRP. In any single experiment, samples were measured in duplicate. mont, CA, USA). Adiponectin and leptin levels were determined by commercial solid-phase enzyme-linked immunosorbent assay kits (B-Bridge International, Sunnyvale, CA, USA; Phoenix Pharmaceuticals, Belmont, CA, USA; and R&D Systems, Inc., USA). The concentration of plasma C-reactive protein (CRP) was measured using a high-sensitivity method (IMMAGE; Beckman Coulter, Immunochemistry Systems, Brea, CA, USA). The intra-assay coefficients of variation were 2.4-2.7% for visfatin, 3.2-7.3% for adiponectin, 3.2-6.9% for leptin, and 4.2-8.7% for hs-CRP. In any single experiment, samples were measured in duplicate. mont, CA, USA). Adiponectin and leptin levels were determined by commercial solid-phase enzyme-linked immunosorbent assay kits (B-Bridge International, Sunnyvale, CA, USA; Phoenix Pharmaceuticals, Belmont, CA, USA; and R&D Systems, Inc., USA). The concentration of plasma C-reactive protein (CRP) was measured using a high-sensitivity method (IMMAGE; Beckman Coulter, Immunochemistry Systems, Brea, CA, USA). The intra-assay coefficients of variation were 2.4-2.7% for visfatin, 3.2-7.3% for adiponectin, 3.2-6.9% for leptin, and 4.2-8.7% for hs-CRP. In any single experiment, samples were measured in duplicate. mont, CA, USA). Adiponectin and leptin levels were determined by commercial solid-phase enzyme-linked immunosorbent assay kits (B-Bridge International, Sunnyvale, CA, USA; Phoenix The eGFR (ml/min/1.73 m 2 ) of individual patients was calculated using the Modification of Diet in Renal Disease (MDRD) Study simplified equation [22] . The patients were stratified by eGFR into CKD stage 1 (≥90 ml/min/1.73m 2 ), stage 2 (60-89 ml/min/1.73m 2 ), stage 3 (30-59 ml/min/1.73m 2 ), and stage 4 (≤29 ml/min/1.73m 2 ) according to Kidney Disease Outcomes Quality Initiative (KDOQI) clinical practice guidelines outlined by the National Kidney Foundation. The 4 stages were compared with respect to clinical characteristics and laboratory data.
Statistical analysis
Data normality was analyzed using the Kolmogorov-Smirnov test. Continuous, normally distributed variables are presented as mean ± SD, and non-normally distributed variables as median (interquartile range). Statistical differences in variables were compared using unpaired Student's ttests, and one-way analysis of variance (ANOVA) for normally distributed variables, followed by Tukey's pairwise comparison. Categorical variables were recorded as frequencies and/or percentages, and inter-group comparisons were analyzed by the chi-square test. Because the distributions of serum total PCS, IS, hs-CRP, and triglycerides were skewed, logarithmically transformed values were used for statistical analysis.
The association of total PCS and IS with CAD was examined by univariate and multivariate logistic regression analysis that contained: 1. total PCS or IS, age, and gender, 2. total PCS or IS, age, gender, BMI, and BP, 3. total PCS or IS, age, gender, BMI, BP, lipid profile, and fasting glucose, and 4. total PCS or IS, age, gender, BMI, BP, lipid profile, fasting glucose, eGFR, and smoking status.
Multivariate adjusted odds ratios (ORs) were applied together with 95% confidence intervals (CI). Pearson's correlation analysis was used to examine the correlations between serum total PCS and IS, and the values of other parameters. Statistical significance was accepted if p < 0.05. All statistical analyses were performed using SAS statistical software, version 8.2 (SAS Institute, Inc., Cary, NC, USA). Table 1 shows the clinical characteristics of control and diabetic subjects. Patients with T2D were older and predominantly male; a higher proportion of these patients smoked, had hypertension, and received anti-hypertensive medication. Furthermore, they had higher levels of BMI, WHR, SBP, fasting glucose, HbA1c, uric acid, blood urea nitrogen, creatinine, total white blood cell (WBC) count, hs-CRP, total PCS, and IS than controls. Also, they exhibited lower levels of serum total cholesterol, HDL-C, LDL-C, and eGFR than controls. Table 1 shows the comparison between T2D in patients with and without CAD. Patients with T2D and CAD were older and predominantly male. A significantly greater proportion of them smoked, had hypertension and/or dyslipidemia, were being treated with an anti-hypertensive drug, had higher WHR, fasting glucose, HbA1C, triglycerides, creatinine, total PCS, and IS levels, and had lower SBP, HDL-C, and eGFR levels. No significant difference in total PCS and IS levels was found between untreated T2D patients and patients treated with statins (5.5 ± 6.7 vs. 4.4 ± 5.3, p = 0.198 for total PCS; 1.8 ± 3.7 vs. 1.5 ± 4.1, p = 0.590 for IS). Table 2 shows that decreased eGFR values, and increased total PCS and IS levels, were noted in 3vessel disease and CAD patients. We subdivided the distribution of eGFR into pooled data, according to CKD classification status, to examine serum total PCS and IS levels with respect to risk for CAD in different CKD classification statuses. Stage 4 patients (eGFR < 29 ml/min/1.73 m 2 ) had a significantly higher mean age, frequency of T2D, CAD, and 3-vessel disease, as well as higher WHR, fasting glucose, uric acid, creatinine, total WBC count, hs-CRP, adiponectin, visfatin, leptin, total PCS, and IS levels. However, they had lower BMI than did stage 1, 2, or 3 patients according to the CKD classification ( Table 2) .
Results
Univariate and multivariate logistic regression analysis showed that serum total PCS and IS concentrations were significantly associated with CAD, even after controlling for anthropometric variables, BP, lipid profile, fasting glucose, eGFR, and smoking status ( Table 3 and Figure 1 ). Moreover, serum levels of total PCS and IS were positively related to Agatston calcium scores, volume calcium scores, Gensini scores, adiponectin, visfatin, leptin, and total WBC count. These levels were negatively correlated with eGFR (all p < 0.05) ( Table 4 ).
Discussion
Previous research indicated that total PCS and IS play potential roles in the development of uremic vascular complications [23] . To our knowledge, the current study is the first report to address the significant association between total PCS and IS levels and CAD in T2D patients. It showed that total PCS and IS levels were significantly corre- lated with renal function deterioration. They were also related to Gensini scores, calcium scores, total WBC counts, and adipocytokines (adiponectin, visfatin, and leptin). Diabetic nephropathy with GFR deterioration is a major factor in CKD etiology, and an important early complication linked with future diabetic cardiovascular morbidity and mortality [24, 25] . Current evidence shows that serum total PCS and IS increase markedly with a GFR of < 60 ml/h [26] , and promote the progression of renal failure [27] . These are not only biomarkers for renal function, but actively participate in the development of diseases [27] . IS and PCS share various similarities, including their production by gut bacteria, metabolism by the kidney, strong albumin binding with low dialytic clearance [28] , and a critical role in cardiovascular morbidity and mortality in advanced CKD patients [29, 30] . However, Meijers et al. demonstrated that total IS and PCS serum concentrations are not associated with each other in dialysis patients, pointing to different metabolic pathways, and non-interchangeable risk markers [31, 32] . Furthermore, there are several different molecular mechanisms between PCS and IS. PCS significantly increases the percentage of leukocytes displaying oxidative burst activity at baseline. It induces the shedding of endothelial microparticles in the absence of overt endothelial damage in vitro, and is independently associated with the number of endothelial microparticles in hemodialysis patients [33] . This suggests that PCS contributes to the propensity for vascular disease in patients with chronic renal failure. IS causes endothelial and vascular dysfunction by promoting vascular smooth muscle cell proliferation through the activation of platelet-derived growth factor receptors and mitogen-activated protein kinase pathways [34, 35] . These consequences are clinically associated with increased aortic calcification and vascular stiffness [30] . Moreover, IS and PCS share the same albumin binding site, for which they are clinically competitive binding inhibitors [31] . The consequence of diabetes-related CKD, with the accumulation of these two compounds, is that it has the capacity to interfere with both the kidney and the cardiovascular system. This causes a degree of endothelial damage that accelerates atherosclerosis and creates cardiovascular damage, as shown in our present study [26, [36] [37] [38] .
An interesting finding of our study is that serum total PCS and IS levels are significantly, and positively, associated with total WBC counts and coronary inflammatory adipocytokines (e.g., adiponectin, leptin, and visfatin). The latter are classified into the middle molecules of uremic solutes, and accumulated when renal function deteriorates [39] . Our previous report showed that leukocytes are activated and secrete cytokines in the diabetic state, and that leptin stimulates leukocyte proliferation and differentiation which contributes to the development and progression of nephropathy in patients with T2D [40] .
The relationship established by high total WBC counts and high adiponectin, leptin, and visfatin levels are significantly associated with coronary atherosclerosis, platelet function activation, increased incidence of acute coronary syndrome and major adverse cardiovascular events [41] [42] [43] [44] [45] [46] . Moreover, the effects of specific uremic retention solutes (especially middle and protein-bound molecules) on platelet and leukocyte functions, suggest a role for these solutes in the initiation and progression of renal failure-related atherosclerosis [47] . However, elevated total PCS and IS concentrations, and their significant association with total WBC counts and adipocytokines in T2D patients with CAD, indicate that increased risk of coronary atherosclerosis in such patients may involve the aforementioned mechanisms.
Previous reports have demonstrated a gradual but significant increase in serum total PCS and IS, as CKD worsens. This has been associated with cardiovascular mortality risk [29, 30] . In the present study, the patients were divided into different stages of CKD, and showed a diversity of common measurable risk factors. Our findings suggest that serum total PCS and IS levels are novel predictors of renal progression. Also, they provide additional information beyond baseline renal function, as well as other traditional and uremia-related predictors. Furthermore, the diabetic CAD group had clinically more compromised renal function compared to the diabetic non-CAD group. This may cause impaired renal clearance, and lead to a marked increase in serum total PCS and IS concentrations. Also, it may contribute to coronary atherosclerosis in diabetic CAD patients; but further experience and more data are required to verify the statement.
Limitations of this study are firstly that blood samples were obtained without stopping the antidiabetic medications in this group of patients. However, anti-diabetic drugs and insulin treatments were not significantly different between patients with T2D with, or without, CAD. Secondly, no free form of PCS or IS data were available in this study. In future studies, it would be interesting to investigate their relationships with diabetic nephropathy.
In conclusion, serum total PCS and IS levels were increased in patients with T2D and CAD. Elevated PCS and IS levels in these patients were associated with renal function deterioration, inflammation, and coronary atherosclerosis.
